Related Experiment Video
Updated: Jul 11, 2026
04:42
Developing a Rat Model for Bipolar Disorder
Published on: May 2, 2025
Pharmacogenetics in modern psychiatry
Alma Mihaljević-Peles1, Nada Bozina, Marina Sagud
1Clinical Hospital Centre Zagreb Kispatićeva 12, 10000 Zagreb, Croatia. apeles@mef.hr
Psychiatria Danubina
|October 5, 2007
Summary
Genetic variations influence antidepressant response. The SERTPR-LL genotype may predict better treatment outcomes for major depressive disorder (MDD) patients taking paroxetine, unlike other tested variants.
Area of Science:
- Pharmacogenetics
- Psychiatric pharmacotherapy
- Molecular psychiatry
Background:
- Predicting patient response to psychiatric medications remains challenging.
- Genetic variations in drug-metabolizing enzymes, transporters, and targets contribute to treatment heterogeneity.
- Identifying reliable genetic predictors for antidepressant efficacy and adverse effects is clinically valuable.
Purpose of the Study:
- To investigate the association between genetic polymorphisms of the serotonin transporter (SERT) and multidrug resistance protein 1 (MDR1) and the therapeutic response to paroxetine in major depressive disorder (MDD) patients.
- To determine if specific SERT and MDR1 genotypes can predict treatment outcomes and inform personalized pharmacotherapy.
Main Methods:
- Genotyping of serotonin transporter (SERT) gene (SLC6A4) and MDR1 gene (ABCB1) polymorphisms in MDD patients.
- Assessing patient response to paroxetine treatment using standardized clinical scales.
- Statistical analysis to correlate specific genotypes with treatment efficacy and response.
Main Results:
- The SERTPR-LL genotype was significantly associated with a better treatment response to paroxetine in MDD patients compared to the SS genotype.
- No significant association was found between the MDR1 gene variants (G2677T and C3435T) and therapeutic response to paroxetine in this patient cohort.
Conclusions:
- The SERTPR-LL genotype may serve as a potential predictive biomarker for favorable response to paroxetine treatment in MDD.
- Further research is warranted to validate these findings and explore the combined effects of multiple genetic factors in predicting antidepressant response.
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:28Human Genetics
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...